The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials
Frontiers in Stroke · 20.06.2024 · 3
DOI: 10.3389/fstro.2024.1363954 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Stroke, online erschienen am 20.06.2024. Verfasst von Hala F Azhari und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
New classes of antidiabetic drugs reportedly lower the risk of cardiovascular events. This review summarizes the evidence for the effects of these drugs on the risk of stroke in diabetic individuals.
Methods
Multiple databases that report stroke outcome data were scrutinized for clinical trials (from inception to June 25, 2023), compared sodium-glucose cotransporter 2 inhibitors (SGLT2-Is), glucagon-like peptide-1 receptor agonists (GLP1-RAs), and dipeptidyl peptidase-4 inhibitors (DPP4-Is), vs. other antidiabetic drugs and placebo.
Results
Among the 960 identified trials, 259 satisfied the eligibility criteria. Among these, 177 and 82 trials reported at least one or no stroke events, respectively. In total, 208, 19, and 32 trials had a low, unclear, and high risk of bias, respectively. SGLT2-Is use did not decrease the risk of non-fatal hemorrhagic or ischemic stroke (risk ratio (RR) 0.96; 95% CI 0.87 to 1.06; P = 0.42) vs. either active comparators or placebo. GLP1-RAs use significantly decreased stroke risk (RR: 0.84, 95% CI [0.77, 0.93], p = 0.0005) and ischemic stroke (RR: 0.85, 95% CI [0.77, 0.94], p = 0.002) vs. placebo. However, GLP1-RAs use did not decrease hemorrhagic events vs. active comparators or placebo. DPP4-Is use did not decrease the risk of non-fatal hemorrhagic or ischemic stroke (RR: 0.91; 95% CI [0.83, 1.01], p = 0.07) vs. active comparators or placebo. For all classes, fatal stroke risk did not decrease vs. active comparators or placebo, and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group scores were moderate.
Discussion
The use of GLP1-RAs, but not SGLT2-Is or DPP4-Is, may decrease non-fatal stroke risk. Considering these results, the findings may inform the treatment of diabetic people at risk of stroke and the design of new antidiabetic interventional trials. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42017067889 , identifier 42017067889.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine and Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
Zitieren
APA
Azhari, H. F., & Dawson, J. (2024). The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials. Frontiers in Stroke, 3. https://doi.org/10.3389/fstro.2024.1363954
Vancouver
Azhari HF, Dawson J. The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials. Frontiers in Stroke. 2024;3. doi:10.3389/fstro.2024.1363954
BibTeX
@article{Azhari2024,
author = {Azhari, Hala F and Dawson, Jesse},
title = {The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials},
journal = {Frontiers in Stroke},
year = {2024},
volume = {3},
doi = {10.3389/fstro.2024.1363954}
}
EUVIMED